Get in here before November 14, 2019. On this date an FDA Advisory Committee (AdCom) is scheduled to meet to discuss Amarin’s (AMRN) …
Most biotech stocks have been under pressure recently, but as we approach the end of the year, many analysts are quite bullish as …
2019 has been a good year for the stock market. Year-to-date, both the S&P 500 and the Nasdaq are up 15% and 19%, …
Wall Street loves growth stocks — and for good reason. In 2018, according to Bank of America, “growth” oriented mutual funds outperformed “value” …
One week ago, Stifel analyst Derek Archila reiterated his “buy” rating on anti-cholesterol drugmaker Amarin (AMRN). He did this partly because he liked …
In an acronym-heavy update, Stifel analyst Derek Archila reiterated his “buy” rating on anti-cholesterol drugmaker Amarin Corporation (AMRN) following the company’s Q2 earnings …
Last week, anti-cholesterol drugmaker Amarin (AMRN) reported a better-than-expected $0.07-per-share loss on $73.
Anti-cholesterol drugmaker Amarin (AMRN) reported a better-than-expected $0.07-per-share loss on Wednesday on $73.
With primary care clinicians playing an ever-increasing role in the management of diabetes, staying on top of new developments in the American Diabetes …
Do you have high cholesterol? Investors in Amarin (AMRN) kind of hope that you do — but ideally, not too high.
